The purpose of this study is to identify and genomically-characterize individuals with genetically unexplained neurodevelopmental disorders, such as epilepsy. The overarching goal is to provide patients with improved information about the underlying genetic basis of their disorder and illuminate novel genetically-defined treatment approaches in the future.

The purpose of the study is to identify certain processes following brain injury that may be associated with the risk of developing epilepsy.

we want to learn more about seizure activity while a patient with epilepsy is not seizing or is at "rest" using data from resting state intracranial EEG (rs-iEEG) and resting state functional MRI (rs-fMRI).

This study compares two dose strengths of a new epilepsy medicine to placebo for treatment of refractory focal onset epilepsy as measured by the change in 28-day average seizure frequency.